Enteric-Coated Cholestyramine Pellets for Targeted Colon Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bile acid malabsorption, particularly those using cholestyramine, are associated with significant side effects such as constipation, interactions with other drugs, and malabsorption of fats and fat-soluble vitamins, and require high doses and frequent administration, which can lead to patient non-compliance due to poor taste and texture.
Innovation Solution
Development of an oral formulation comprising small, stable cholestyramine pellets coated with a diffusion-controlled inner coating and an enteric outer coating, designed for targeted release in the colon, allowing for reduced doses and minimizing interactions with other gastrointestinal components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholestyramine is administered orally to treat bile acid malabsorption, then excess bile acids are bound in the gastrointestinal tract, but significant side effects occur including constipation, interactions with other drugs, and malabsorption of fats and fat-soluble vitamins
Solution Approach 1:
The invention segments the gastrointestinal tract into different regions (small intestine vs. colon) and targets cholestyramine release specifically to the colon using enteric-coated pellets. This segmentation allows the drug to bind bile acids where they accumulate in excess without exposing the entire GI tract to the drug, thereby reducing side effects while maintaining effectiveness.
Solution Approach 2:
The invention applies local quality by creating a formulation with non-uniform release properties: the enteric coating ensures cholestyramine is released only in the colon (local region) rather than throughout the entire GI tract. This localized release concentrates the therapeutic effect where needed while minimizing harmful interactions in other regions.
2Reliability
If high doses of cholestyramine are administered to ensure adequate binding of bile acids, then therapeutic effect is improved, but patient compliance deteriorates due to poor taste and texture requiring frequent administration
Solution Approach 1:
The formulation uses multiple small pellets instead of a single large dose, allowing the total therapeutic dose to be divided into smaller units. This segmentation improves palatability and ease of administration while maintaining the required total dose for effective bile acid binding.
Solution Approach 2:
The enteric coating changes the release parameters of cholestyramine, allowing it to be administered at lower frequencies since the coated pellets provide sustained release in the colon. This parameter change from immediate to delayed release improves compliance without sacrificing therapeutic effect.
3Reliability
If cholestyramine is released in the small intestine, then bile acid binding begins early in the GI tract, but interactions with other drugs and malabsorption of nutrients occur
Solution Approach 1:
The invention segments the site of action to the colon specifically, using enteric-coated pellets that resist dissolution in the small intestine. This spatial segmentation prevents cholestyramine from interacting with other drugs and nutrients in the upper GI tract while still allowing it to bind bile acids in the colon where they accumulate.
Solution Approach 2:
The enteric coating acts as an intermediary that protects cholestyramine from releasing in the small intestine. This intermediary layer prevents premature interaction between cholestyramine and other GI contents, allowing the drug to reach the colon where it can safely bind bile acids without causing harmful interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves greater than 70% cholestyramine release in the colon, reducing side effects and improving patient compliance by minimizing exposure to the small intestine, thus effectively binding excess bile acids while maintaining absorption of essential nutrients.
Implementation Method 1
coated with a diffusion-controlled inner coating and an enteric outer coating
Implementation Method 2
coated with a diffusion-controlled inner coating and an enteric outer coating
Implementation Method 3
Cholestyramine is a strongly basic anion-exchange resin that is practically insoluble in water and is not absorbed from the gastrointestinal tract. Instead, it absorbs and combines with the bile acids in the intestine to form an insoluble complex.
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.